List of Tables
    Table 1. Cancer Immunotherapies CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Cancer Immunotherapies Market Trends
    Table 3. Cancer Immunotherapies Market Drivers
    Table 4. Cancer Immunotherapies Market Challenges
    Table 5. Cancer Immunotherapies Market Restraints
    Table 6. Global Cancer Immunotherapies Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Cancer Immunotherapies Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Cancer Immunotherapies Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Cancer Immunotherapies Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Cancer Immunotherapies Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Cancer Immunotherapies Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Cancer Immunotherapies Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Cancer Immunotherapies Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Cancer Immunotherapies Sales Share by Manufacturer, 2017-2022
    Table 15. Global Cancer Immunotherapies Price by Manufacturer (2017-2022) & (USD/Unit)
    Table 16. Global Cancer Immunotherapies Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapies as of 2021)
    Table 18. Top Players of Cancer Immunotherapies in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Cancer Immunotherapies Product Type
    Table 20. Date of International Manufacturers Enter into Cancer Immunotherapies Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Cancer Immunotherapies Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Cancer Immunotherapies Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Cancer Immunotherapies Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Cancer Immunotherapies Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Cancer Immunotherapies Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Cancer Immunotherapies Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Cancer Immunotherapies Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Cancer Immunotherapies Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Cancer Immunotherapies Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Cancer Immunotherapies Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Cancer Immunotherapies Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Cancer Immunotherapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Cancer Immunotherapies Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Cancer Immunotherapies Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Cancer Immunotherapies Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Cancer Immunotherapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Cancer Immunotherapies Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Cancer Immunotherapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Cancer Immunotherapies Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Cancer Immunotherapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Amgen Corporation Information
    Table 43. Amgen Description and Business Overview
    Table 44. Amgen Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 45. Amgen Cancer Immunotherapies Product
    Table 46. Amgen Recent Development
    Table 47. AstraZeneca Corporation Information
    Table 48. AstraZeneca Description and Business Overview
    Table 49. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 50. AstraZeneca Product
    Table 51. AstraZeneca Recent Development
    Table 52. Roche Corporation Information
    Table 53. Roche Description and Business Overview
    Table 54. Roche Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 55. Roche Product
    Table 56. Roche Recent Development
    Table 57. Bristol-Myers Squibb Corporation Information
    Table 58. Bristol-Myers Squibb Description and Business Overview
    Table 59. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 60. Bristol-Myers Squibb Product
    Table 61. Bristol-Myers Squibb Recent Development
    Table 62. Bayer Corporation Information
    Table 63. Bayer Description and Business Overview
    Table 64. Bayer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 65. Bayer Product
    Table 66. Bayer Recent Development
    Table 67. Merck Corporation Information
    Table 68. Merck Description and Business Overview
    Table 69. Merck Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 70. Merck Product
    Table 71. Merck Recent Development
    Table 72. ARMO BioSciences (Eli Lilly) Corporation Information
    Table 73. ARMO BioSciences (Eli Lilly) Description and Business Overview
    Table 74. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 75. ARMO BioSciences (Eli Lilly) Product
    Table 76. ARMO BioSciences (Eli Lilly) Recent Development
    Table 77. Novartis Corporation Information
    Table 78. Novartis Description and Business Overview
    Table 79. Novartis Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 80. Novartis Product
    Table 81. Novartis Recent Development
    Table 82. Pfizer Corporation Information
    Table 83. Pfizer Description and Business Overview
    Table 84. Pfizer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 85. Pfizer Product
    Table 86. Pfizer Recent Development
    Table 87. Johnson & Johnson Corporation Information
    Table 88. Johnson & Johnson Description and Business Overview
    Table 89. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 90. Johnson & Johnson Product
    Table 91. Johnson & Johnson Recent Development
    Table 92. AbbVie Corporation Information
    Table 93. AbbVie Description and Business Overview
    Table 94. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 95. AbbVie Product
    Table 96. AbbVie Recent Development
    Table 97. Gilead Sciences Corporation Information
    Table 98. Gilead Sciences Description and Business Overview
    Table 99. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 100. Gilead Sciences Product
    Table 101. Gilead Sciences Recent Development
    Table 102. Key Raw Materials Lists
    Table 103. Raw Materials Key Suppliers Lists
    Table 104. Cancer Immunotherapies Customers List
    Table 105. Cancer Immunotherapies Distributors List
    Table 106. Research Programs/Design for This Report
    Table 107. Key Data Information from Secondary Sources
    Table 108. Key Data Information from Primary Sources
List of Figures
    Figure 1. Cancer Immunotherapies Product Picture
    Figure 2. Global Cancer Immunotherapies Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Cancer Immunotherapies Market Size 2017-2028 (US$ Million)
    Figure 4. Global Cancer Immunotherapies Sales 2017-2028 (K Units)
    Figure 5. United States Cancer Immunotherapies Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Cancer Immunotherapies Market Size 2017-2028 (US$ Million)
    Figure 7. United States Cancer Immunotherapies Sales 2017-2028 (K Units)
    Figure 8. United States Cancer Immunotherapies Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Cancer Immunotherapies Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Cancer Immunotherapies Report Years Considered
    Figure 11. Product Picture of Monoclonal Antibodies (MABs)
    Figure 12. Product Picture of Cancer Vaccines
    Figure 13. Product Picture of Immunomodulators
    Figure 14. Product Picture of Adoptive Cell transfer
    Figure 15. Product Picture of Checkpoint Inhibitors
    Figure 16. Global Cancer Immunotherapies Market Share by Type in 2022 & 2028
    Figure 17. Global Cancer Immunotherapies Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 18. Global Cancer Immunotherapies Sales Market Share in Value by Type (2017-2028)
    Figure 19. Global Cancer Immunotherapies Sales by Type (2017-2028) & (K Units)
    Figure 20. Global Cancer Immunotherapies Sales Market Share in Volume by Type (2017-2028)
    Figure 21. Global Cancer Immunotherapies Price by Type (2017-2028) & (USD/Unit)
    Figure 22. United States Cancer Immunotherapies Market Share by Type in 2022 & 2028
    Figure 23. United States Cancer Immunotherapies Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 24. United States Cancer Immunotherapies Sales Market Share in Value by Type (2017-2028)
    Figure 25. United States Cancer Immunotherapies Sales by Type (2017-2028) & (K Units)
    Figure 26. United States Cancer Immunotherapies Sales Market Share in Volume by Type (2017-2028)
    Figure 27. United States Cancer Immunotherapies Price by Type (2017-2028) & (USD/Unit)
    Figure 28. Product Picture of Breast Cancer
    Figure 29. Product Picture of Leukemia
    Figure 30. Product Picture of Lymphoma
    Figure 31. Product Picture of Melanoma
    Figure 32. Product Picture of Colorectal Cancer
    Figure 33. Product Picture of Non-Small Cell Lung Cancer
    Figure 34. Global Cancer Immunotherapies Market Share by Application in 2022 & 2028
    Figure 35. Global Cancer Immunotherapies Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 36. Global Cancer Immunotherapies Sales Market Share in Value by Application (2017-2028)
    Figure 37. Global Cancer Immunotherapies Sales by Application (2017-2028) & (K Units)
    Figure 38. Global Cancer Immunotherapies Sales Market Share in Volume by Application (2017-2028)
    Figure 39. Global Cancer Immunotherapies Price by Application (2017-2028) & (USD/Unit)
    Figure 40. United States Cancer Immunotherapies Market Share by Application in 2022 & 2028
    Figure 41. United States Cancer Immunotherapies Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 42. United States Cancer Immunotherapies Sales Market Share in Value by Application (2017-2028)
    Figure 43. United States Cancer Immunotherapies Sales by Application (2017-2028) & (K Units)
    Figure 44. United States Cancer Immunotherapies Sales Market Share in Volume by Application (2017-2028)
    Figure 45. United States Cancer Immunotherapies Price by Application (2017-2028) & (USD/Unit)
    Figure 46. North America Cancer Immunotherapies Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 47. North America Cancer Immunotherapies Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 48. U.S. Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Canada Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Europe Cancer Immunotherapies Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 51. Europe Cancer Immunotherapies Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 52. Germany Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. France Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. U.K. Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Italy Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Russia Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Asia-Pacific Cancer Immunotherapies Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 58. Asia-Pacific Cancer Immunotherapies Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 59. China Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Japan Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. South Korea Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. India Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Australia Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Taiwan Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Indonesia Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Thailand Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Malaysia Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Philippines Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Latin America Cancer Immunotherapies Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 70. Latin America Cancer Immunotherapies Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 71. Mexico Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Brazil Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Argentina Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Middle East & Africa Cancer Immunotherapies Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 75. Middle East & Africa Cancer Immunotherapies Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 76. Turkey Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. Saudi Arabia Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. U.A.E Cancer Immunotherapies Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 79. Cancer Immunotherapies Value Chain
    Figure 80. Cancer Immunotherapies Production Process
    Figure 81. Channels of Distribution
    Figure 82. Distributors Profiles
    Figure 83. Bottom-up and Top-down Approaches for This Report
    Figure 84. Data Triangulation
    Figure 85. Key Executives Interviewed